IL-1α-primed MSC-derived conditioned medium treatment led to ∼30% reduction in lesion volume and improved behavioral outcomes and neurological score in a mouse model of stroke (Cunningham et al., 2020). This evidence concerns the gene IL1A and stroke disorder.